Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 7INDUSTRY 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neoplasms 1Keratosis, Actinic 1Heart Failure 1Gastrointestinal Neoplasms 1Disease 1Colorectal Neoplasms 1Breast Neoplasms 1Biliary Tract Neoplasms 1Arrhythmias, Cardiac 1

Interventions

Bevacizumab 188Fluorouracil 150Leucovorin 134Cetuximab 127Irinotecan 114Oxaliplatin 108pembrolizumab 96Capecitabine 82IFL protocol 53Panitumumab 43regorafenib 42Nivolumab 42Folfox protocol 40Gemcitabine 30trifluridine tipiracil drug combination 27Cisplatin 24Carboplatin 24atezolizumab 22Pemetrexed 20Paclitaxel 20Drug Therapy 20130-nm albumin-bound paclitaxel 17Trastuzumab 14encorafenib 13Trifluridine 13Ipilimumab 13HMPL-013 13tislelizumab 12spartalizumab 11Docetaxel 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Colorectal Neoplasms × Control Groups × Clear all
NCT02870582 2022-11-29

Donafenib for Previously Treated Metastatic Colorectal Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Completed
536 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡